Nitric Oxide and Teratogenesis: An Update

被引:10
作者
Tiboni, Gian Mario [1 ]
Ponzano, Adalisa [1 ]
机构
[1] Univ G dAnnunzio, Dept Med & Aging Sci, Chieti, Italy
关键词
Nitric oxide; nitric oxide synthase; nitric oxide synthase inhibitors; teratology; birth defects; limb defects; axial skeletal defects; neural tube defects; cardiovascular defects; ESTER L-NAME; METHYL-ESTER; LIMB TERATOGENICITY; VASCULAR DEVELOPMENT; SYNTHASE INHIBITION; MECHANISTIC MODEL; COPPER-DEFICIENCY; VALPROIC ACID; FREE-RADICALS; THALIDOMIDE;
D O I
10.2174/1381612820666140205150437
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nitric oxide (NO), generated by NO synthase (NOS) enzymes, is an important bioactive molecule involved in the regulation of several biological phenomena that are crucial for organogenesis, including gene expression, cell growth, matrix remolding, proliferation, differentiation and apoptosis. The expression of NOS isoforms in embryonic tissues is temporally and spatially regulated, and disruption of endogenous NO can lead to developmental defects. Maternal treatment with pan NOS inhibitors during early organogenesis caused severe malformations of the axial skeleton. In utero exposure during the fetal period induced limb reduction defects of vascular origin. Knock-out mice have been used to define the role of the various NOS isoforms on the origin of the abnormal development. Cardiovascular malformations, limb reduction defects, reduced growth and reduced survival have been observed in knock-out mice with targeted disruption of endothelial NOS (eNOS). Limited morphological changes were observed in mice lacking inducible NOS (iNOS) or neuronal NOS n(NOS). Results obtained with in vitro studies suggest that optimal levels of NO are required for neural tube closure. Disregulation of NO production was also recently proposed as a contributing mechanism in the origin of malformations associated with exposure to known environmental teratogens, such as valproic acid, thalidomide, copper deficiency, and diabetes.
引用
收藏
页码:5443 / 5447
页数:5
相关论文
共 80 条
  • [1] Role of nitric oxide in chick embryonic organogenesis and dysmorphogenesis
    Alexander, Peter G.
    Chau, Lillian
    Tuan, Rocky S.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2007, 79 (08) : 581 - 594
  • [2] BECERRA JE, 1990, PEDIATRICS, V85, P1
  • [3] Nitric oxide (NO) - Biogeneration, regulation, and relevence to human diseases
    Bian, K
    Murad, F
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2003, 8 : D264 - D278
  • [4] Nitric oxide synthase expression and role during cardiomyogenesis
    Bloch, W
    Fleischmann, BK
    Lorke, DE
    Andressen, C
    Hops, B
    Hescheler, J
    Addicks, K
    [J]. CARDIOVASCULAR RESEARCH, 1999, 43 (03) : 675 - 684
  • [5] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS
    DAMATO, RJ
    LOUGHNAN, MS
    FLYNN, E
    FOLKMAN, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) : 4082 - 4085
  • [6] Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors
    Duenas-Gonzalez, Alfonso
    Candelaria, Myrna
    Perez-Plascencia, Carlos
    Perez-Cardenas, Enrique
    de la Cruz-Hernandez, Erick
    Herrera, Luis A.
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 (03) : 206 - 222
  • [7] Further evidence for the role of free radicals in the limb teratogenicity of L-NAME
    Fantel, AG
    Person, RE
    [J]. TERATOLOGY, 2002, 66 (01) : 24 - 32
  • [8] The teratogenicity of N-omega-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, in rats
    Fantel, AG
    Nekahi, N
    Shepard, TH
    Cornel, LM
    Unis, AS
    Lemire, RJ
    [J]. REPRODUCTIVE TOXICOLOGY, 1997, 11 (05) : 709 - 717
  • [9] Fantel AG, 1999, TERATOLOGY, V60, P151, DOI 10.1002/(SICI)1096-9926(199909)60:3<151::AID-TERA11>3.0.CO
  • [10] 2-E